Mena FN14d
Clover Announces Positive Clinical Data For RSV Vaccine Candidate SCB-1019 Compared Head-To-Head Versus GSK's AREXVY
"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...
Vietnam Investment Reviev14d
Synechron Acquires Cloobees, a global Salesforce summit partner
Synechron, Inc., a leading global digital transformation consulting firm, announced today that it has acquired Cloobees, an award winning, top-tier Salesforce implementation partner. Cloobees will add ...
Vietnam Investment Reviev14d
Trip.Biz Unveils New Product Matrix to Digitalise Business Travel for the Japanese Market
Trip.com Group's corporate travel management brand, Trip.Biz, recently hosted its annual conference, 'Trip.Biz Transform 2024,' in Singapore. Japan's Travel Management Company (TMC) market is highly ...
MarketWatch14d
GSK Net Profit Expected to Rise, Turnover to Fall -- Earnings Preview
WHAT TO WATCH --VACCINES: Investors' concerns linger over sales expectations for the company's respiratory syncytial virus vaccine Arexvy and its best-selling shingles vaccine Shingrix for the ...
PipelineReview.com14d
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
The 2023 approval of the world’s first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated with RSV ...
Eagle-Tribune14d
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
The 2023 approval of the world's first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated ...
Ontario News14d
Free Flu Shot and New COVID-19 Vaccines Now Available Across Ontario
We are pleased that AREXVY remains among the vaccines being offered this season, and that older Ontarians will continue to benefit from the protection offered by RSV vaccines." "As a company invested ...
pulmonologyadvisor14d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...
Seeking Alpha16d
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
Pharmabiz17d
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...
Business Insider17d
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...